Literature DB >> 30951820

Pharmacological characterization of the 3D MucilAir™ nasal model.

Clément Mercier1, Elodie Jacqueroux2, Zhiguo He3, Sophie Hodin4, Samuel Constant5, Nathalie Perek6, Delphine Boudard7, Xavier Delavenne8.   

Abstract

The preclinical evaluation of nasally administered drug candidates requires screening studies based on in vitro models of the nasal mucosa. The aim of this study was to evaluate the morpho-functional characteristics of the 3D MucilAir™ nasal model with a pharmacological focus on [ATP]-binding cassette (ABC) efflux transporters. We initially performed a phenotypic characterization of the MucilAir™ model and assessed its barrier properties by immunofluorescence (IF), protein mass spectrometry and examination of histological sections. We then focused on the functional expression of the ABC transporters P-glycoprotein (P-gp), multidrug resistance associated protein (MRP)1, MRP2 and breast cancer resistance protein (BCRP) in bidirectional transport experiments. The MucilAir™ model comprises a tight, polarized, pseudo-stratified nasal epithelium composed of fully differentiated ciliated, goblet and basal cells. These ABC transporters were all expressed by the cell membranes. P-gp and BCRP were both functional and capable of actively effluxing substrates. The MucilAir™ model could consequently represent a potent tool for evaluating the interaction of nasally administered drugs with ABC transporters.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABC transporters; Bidirectional transport; Drug delivery; In vitro model; MucilAir™; Nasal barrier

Mesh:

Substances:

Year:  2019        PMID: 30951820     DOI: 10.1016/j.ejpb.2019.04.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Multiparametric investigation of non functionalized-AGuIX nanoparticles in 3D human airway epithelium models demonstrates preferential targeting of tumor cells.

Authors:  Lucie Sancey; Odile Sabido; Zhiguo He; Fabien Rossetti; Alain Guignandon; Valérie Bin; Jean-Luc Coll; Michèle Cottier; François Lux; Olivier Tillement; Samuel Constant; Christophe Mas; Delphine Boudard
Journal:  J Nanobiotechnology       Date:  2020-09-10       Impact factor: 10.435

2.  Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.

Authors:  Domizia Baldassi; Bettina Gabold; Olivia Merkel
Journal:  Adv Nanobiomed Res       Date:  2021-05-06

3.  Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.

Authors:  Fabio Fais; Reda Juskeviciene; Veronica Francardo; Stéphanie Mateos; Manuela Guyard; Cécile Viollet; Samuel Constant; Massimo Borelli; Ilja P Hohenfeld
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

4.  A Complete In Vitro Toxicological Assessment of the Biological Effects of Cerium Oxide Nanoparticles: From Acute Toxicity to Multi-Dose Subchronic Cytotoxicity Study.

Authors:  Adrián García-Salvador; Alberto Katsumiti; Elena Rojas; Carol Aristimuño; Mónica Betanzos; Marta Martínez-Moro; Sergio E Moya; Felipe Goñi-de-Cerio
Journal:  Nanomaterials (Basel)       Date:  2021-06-16       Impact factor: 5.076

5.  Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats.

Authors:  Tomoyuki Furubayashi; Daisuke Inoue; Noriko Nishiyama; Akiko Tanaka; Reiko Yutani; Shunsuke Kimura; Hidemasa Katsumi; Akira Yamamoto; Toshiyasu Sakane
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

6.  A comparison of three mucus-secreting airway cell lines (Calu-3, SPOC1 and UNCN3T) for use as biopharmaceutical models of the nose and lung.

Authors:  Diane F Lee; Michael I Lethem; Alison B Lansley
Journal:  Eur J Pharm Biopharm       Date:  2021-07-29       Impact factor: 5.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.